Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed‐ratio combinations of basal insulin and a glucagon‐like peptide‐1 receptor agonist

Bibliographic Details
Main Authors:	Luděk Horváth, Peter Novodvorský, Martin Haluzík
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Diabetes, Obesity and Metabolism
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetes
by: Irl B. Hirsch, et al.
Published: (2024)

Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed‐ratio basal insulin glucagon‐like peptide‐1 receptor agonist combinations?
by: Kevin Cowart, et al.
Published: (2025)

Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes
by: Julio Rosenstock, et al.
Published: (2025)

Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes
by: Jincheng Shen, et al.
Published: (2025)

Treatment intensification following glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE ‐G real‐world study
by: Raffaele Napoli, et al.
Published: (2024)

iGlarLixi : A titrateable fixed‐ratio combination of basal insulin + GLP‐1 receptor agonist—An effective type 2 diabetes treatment option in China
by: Miao Yu
Published: (2025)

Effects of glucagon‐like peptide‐1 receptor agonists on glycated haemoglobin and continuous glucose monitoring metrics as adjunctive therapy to insulin in adults with type 1 diabetes: A meta‐analysis of randomized controlled trials
by: Paschalis Karakasis, et al.
Published: (2024)

FRONTIER : FReeStyle Libre system use in Ontario among people with diabetes in the IC / ES database—Evidence from real‐world practice: Patients on basal insulin, glucagon‐like peptide 1 receptor agonist or oral therapies
by: Alexandria Ratzki‐Leewing, et al.
Published: (2025)

An overview of randomized clinical trials of fixed‐ratio combinations of basal insulin plus GLP ‐ 1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes
by: Geremia B. Bolli, et al.
Published: (2025)

A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
by: Filip K. Knop, et al.
Published: (2024)

Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
by: Yunwen Xu, et al.
Published: (2025)

Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in type 2 diabetes according to baseline glucagon‐like peptide‐1 receptor agonist and sodium‐glucose co‐transporter‐2 inhibitor use: A post hoc analysis of ONWARDS 1–5
by: Tina Vilsbøll, et al.
Published: (2025)

Cost‐utility analysis of once‐weekly insulin icodec and once‐daily insulin glargine in patients with type 2 diabetes receiving basal‐bolus insulin therapy in China
by: Nan Dai, et al.
Published: (2024)

Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
by: Fu‐Shun Yen, et al.
Published: (2025)

What is the ‘real‐world’ experience with fixed‐ratio combination therapy (insulin + GLP ‐1 receptor agonist) in routine clinical practice? Take‐home messages for clinicians regarding key outcomes
by: Juan Pablo Frias
Published: (2025)

Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
by: David C. Klonoff, et al.
Published: (2024)

Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium‐glucose cotransporter‐2 inhibitor and glucagon‐like peptide ‐1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease
by: Shunichiro Tsukamoto, et al.
Published: (2024)

Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
by: Darren Lau, et al.
Published: (2024)

Efficacy and safety of once‐weekly basal insulin therapy in people with type 1 diabetes: A systematic review and meta‐analysis
by: Ludovico Di Gioia, et al.
Published: (2025)

Potential new therapies to preserve lean muscle mass loss when used in combination with glucagon‐like peptide 1 (GLP‐1) receptor agonist being studied
by: Iskandar Idris
Published: (2024)

Real‐world impact of adding a glucagon‐like peptide‐1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium‐glucose co‐transporter‐2 inhibitor: The Impact GLP‐1 CKD study
by: Lisa Chu, et al.
Published: (2024)

Cost‐utility of once‐weekly insulin icodec versus once‐daily basal insulins for type 2 diabetes in China
by: Xichen Tong, et al.
Published: (2026)

Real‐life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use
by: Jochen Seufert, et al.
Published: (2024)

Efficacy of telemedicine on glycaemic control in nursing home residents with type 2 diabetes on basal‐bolus insulin therapy: A randomised controlled trial
by: Ilaria Dicembrini, et al.
Published: (2026)

Getting the measure of the pressure: Optimal assessment of the effects of glucagon‐like peptide‐1 receptor agonists on blood pressure
by: Karen L. Jones, et al.
Published: (2024)

An overview of insulin therapy for the non‐specialist
by: Philip D. Home
Published: (2025)

Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c
by: Stephanie L. Samuels, et al.
Published: (2024)

Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study
by: Yu‐Nan Huang, et al.
Published: (2024)

The effect of glucagon‐like peptide‐1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta‐analysis
by: Yu Zhang, et al.
Published: (2024)

Impact of glucagon‐like peptide‐1 receptor agonism‐based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta‐analysis
by: Deep Dutta, et al.
Published: (2025)

Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials
by: Dongjin Yeo, et al.
Published: (2025)

Correction to “Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study”
Published: (2025)

Geographic variation in sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia
by: Juliana de Oliveira Costa, et al.
Published: (2024)

Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis
by: Ruoyang Jiao, et al.
Published: (2024)

Association between glucagon‐like peptide ‐1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database
by: Tae Hyeon Kim, et al.
Published: (2024)

Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
by: Jason M. Samuels, et al.
Published: (2024)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
by: Iskandar Idris
Published: (2024)

Efficacy and safety of GLP ‐1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta‐analysis
by: Sama M. Abdel‐Rahman, et al.
Published: (2026)

Safety and efficacy of hybrid closed‐loop insulin pump therapy in adolescents and adults with type 1 diabetes in China
by: Jing Shen, et al.
Published: (2025)

Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study
by: Neeta B. Amin, et al.
Published: (2024)

Similar Items

Similar Items